Back

Ascletis reports 24.8% weight loss for ASC36_35FDC in obesity rats

Verifying
  • Ascletis presented preclinical ASC36_35FDC data at the 62nd EASD Annual Meeting.
  • ASC36_35FDC reduced rat body weight 24.8% by Day 14, versus 12.5% and 16.8%.
  • Ascletis reported stability across tested conditions and half-lives supporting monthly or potentially quarterly dosing.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.